A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers.
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2014
At a glance
- Drugs MM 111 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Merrimack Pharmaceuticals
- 20 Mar 2012 Actual patient number (20) added as reported by ClinicalTrials.gov.
- 20 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2011 Phase changed from I/II to I, disease changed from Advanced Her2 Amplified Cancers to Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers, phase 2 tt. part removed, inclusion/ exclusion criterion modified.